Several other brokerages have also recently weighed in on VRTX. William Blair reissued a market perform rating on shares of aTyr Pharma in a report on Tuesday, March 26th. Evercore ISI began coverage on Homology Medicines in a report on Thursday, April 11th. They set an outperform rating and a $29.00 price objective for the company. Goldman Sachs Group raised Lenovo Group from a neutral rating to a buy rating in a report on Thursday, May 23rd. They noted that the move was a valuation call. Leerink Swann cut Vertex Pharmaceuticals from an outperform rating to a market perform rating and set a $185.40 price objective for the company. in a report on Tuesday, March 19th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. reissued a buy rating on shares of BioMarin Pharmaceutical in a report on Sunday, June 2nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seventeen have given a buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of Buy and an average target price of $204.36.
Vertex Pharmaceuticals stock opened at $175.79 on Tuesday. The firm has a 50-day simple moving average of $175.45. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.66. Vertex Pharmaceuticals has a 12-month low of $151.80 and a 12-month high of $195.81. The company has a market capitalization of $45.02 billion, a PE ratio of 62.12, a price-to-earnings-growth ratio of 2.59 and a beta of 1.43.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 10,480 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $175.08, for a total value of $1,834,838.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeffrey M. Leiden sold 33,058 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $175.01, for a total value of $5,785,480.58. Following the completion of the sale, the chief executive officer now owns 136,953 shares in the company, valued at approximately $23,968,144.53. The disclosure for this sale can be found here. Insiders sold a total of 227,804 shares of company stock valued at $39,955,223 over the last quarter. 0.70% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Welch & Forbes LLC lifted its stake in Vertex Pharmaceuticals by 0.8% in the 2nd quarter. Welch & Forbes LLC now owns 175,927 shares of the pharmaceutical company’s stock valued at $32,261,000 after acquiring an additional 1,477 shares in the last quarter. Clark Capital Management Group Inc. lifted its stake in Vertex Pharmaceuticals by 44.2% in the 2nd quarter. Clark Capital Management Group Inc. now owns 1,839 shares of the pharmaceutical company’s stock valued at $337,000 after acquiring an additional 564 shares in the last quarter. HMS Capital Management LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at approximately $184,000. NN Investment Partners Holdings N.V. lifted its stake in Vertex Pharmaceuticals by 9.9% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 38,743 shares of the pharmaceutical company’s stock valued at $7,105,000 after acquiring an additional 3,479 shares in the last quarter. Finally, Evolution Wealth Advisors LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: What is the Quick Ratio?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.